Acanthosis nigricans
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
He mea noa ki te hunga momomo.
relevance score : -100.0%
ReferencesKo te Acanthosis nigricans he whakaaturanga kiri kiri o te ahua o raro. I te nuinga o te wa ka puta ki nga kopa kiri penei i te kaki, i nga kaokao, me te papa, he rite te ahua ki nga papanga pouri me nga tapa kore marama. I te nuinga o te wa e hono ana tenei ahuatanga ki te mate huka (diabetes mellitus) me te parenga o te insulin (insulin resistance), engari he onge, ka tohu pea ki te mate pukupuku (internal malignancy) i roto i te tinana. Ka puta pea na te take o te homoni, na te tango rongoa ranei penei i te steroids (systemic glucocorticoids) me nga pire whakawhanau (oral contraceptives).
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Ko te Acanthosis nigricans (AN) he mate kiri noa e hono ana ki ngā momo take hauora pērā i te parenga insulin (insulin resistance), te mate huka, te momi, ētahi mate pūkūpuku, raruraru homoni, me ngā tauhohenga ki ngā rongoā. Ko te maimoatanga AN e aro ana ki te whakatika i ngā raru hauora. I te timatanga, ka tirohia e ngā tākuta ngā tohu o te insulin resistance syndrome, kei roto ko te momona, te cholesterol teitei, te toto pihi (hypertension), me te mate huka momo 2. He maha ngā wā ka tōhuhia e ngā tākuta te topical retinoids hei kōwhiringa maimoatanga tuatahi, ka taea te awhina i te whakapawera kiri. Heoi, kāore pea rātou e tino whakatutuki i te pouri o te kiri. Ko ētahi atu momo maimoatanga (salicylic acid, podophyllin, urea, calcipotriol) me tono auau.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Te take
I te nuinga o te wa ka pa ki nga tangata iti iho i te 40 tau, he mea tuku iho pea ki te ira, ka pa ana ki te momona me te endocrinopathies, penei i te hypothyroidism, te acromegaly, te mate polycystic ovary, te mate huka-atete ki te insulin, te mate Cushing ranei.
○ Maimoatanga ― OTC Drugs
#40% urea cream